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Abstract: Plant extracts have been traditionally used for various therapeutic applications. By conducting an initial 
screening of several subtropical plants, in this study, we evaluated the anticancer activities of Melia azedarach L. 
The extract from Melia azedarach L. leaves (MLE) show high cytotoxic effects on cancer cells and in vivo mouse and 
dog tumor models. During the initial screening, MLE showed strong antiproliferative activity against HT-29 colon, 
A549 lung, and MKN1 gastric cancer cells. In subsequent tests, using 39 human tumor cell lines, we confirmed the 
potent anticancer activities of MLE. The anticancer activity of MLE was also confirmed in vivo. MLE markedly inhib-
ited the growth of transplanted gastric MKN1 cancer xenografts in mice. To elucidate the mechanism underlying the 
anticancer effects of MLE, MLE-treated MKN1 cells were observed using an electron microscope; MLE treatment 
induced autophagy. Furthermore, western blot analysis of proteins in lysates of MLE-treated cells revealed induc-
tion of light chain 3 (LC3)-II autophagosomal proteins. Thus, MLE appeared to suppress MKN1 cell proliferation by 
inducing autophagy. In addition, in the mouse macrophage cell line J774A.1, MLE treatment induced TNF-α produc-
tion, which might play a role in tumor growth suppression in vivo. We also performed a preclinical evaluation of 
MLE treatment on dogs with various cancers in veterinary hospitals. Dogs with various types of cancers showed a 
mean recovery of 76% when treated with MLE. Finally, we tried to identify the active substances present in MLE. All 
the active fractions obtained by reverse-phase chromatography contained azedarachin B-related moieties, such as 
3-deacetyl-12-hydroxy-amoorastatin, 12-hydroxy-amoorastatin, and 12-hydroxyamoorastaton. In conclusion, MLE 
contains substances with promising anticancer effects, suggesting their future use as safe and effective anticancer 
agents. 
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Introduction
The development of new anticancer agents is 
of great importance to public health. Recent 
progress in molecular oncology has led to the 
development of molecular-targeting technolo-
gies for cancer therapy, and various chemical 
and biological therapeutics have proven effec-
tive in improving patient survival [1, 2]. Typical 
examples include imatinib, gefitinib, and erlo-
tinib, which inhibit the kinase activities of onco-
genic receptor kinases. Despite the progress in 
anti-cancer therapeutics, cancer is the second 
leading cause of mortality globally. The World 
Health Organization estimates that, globally, 14 
million people are suffering from cancer and 
cancer caused 9.6 million deaths in 2018. 
Japan is no exception and the number of can-
cer-related deaths in Japan increased from 
295,864 in 2000 to 353,000 in 2010, an 
increase of ~1% per year [3].
Plant extracts have been used as traditional 
remedies and are sources of several anticancer 
drugs distributed worldwide [4]. Among the first 
drugs from plants used for the treatment of 
cancer are microtubule-targeting agents, tax-
anes, and vinca alkaloids, which include pacli-
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taxel, vinblastine, and vincristine [5-7]. 
Paclitaxel was originally isolated from the bark 
of the Pacific Yew, and vinblastine and vincris-
tine were extracted from the Madagascar peri-
winkle [7, 8]. Inhibitors of DNA topoisomerase I, 
such as topotecan and irinotecan (CPT-11), are 
synthetic analogs of the cytotoxic alkaloid, 
camptothecin (CPT), isolated from the bark and 
stems of the Chinese Happy Tree [9]. Several 
synthetic analogs of CPT have better aqueous 
solubility, lower toxicity, and greater antitumor 
efficacy than the parent drug, among which iri-
notecan and topotecan are approved for clini-
cal use [9, 10]. 
In this study, we purified and characterized 
potential anticancer compounds extracted 
from the leaf of the Melia tree (Melia azedarach 
L.) collected from the mainland of the Okinawa 
region. By exploring over 2,000 subtropical 
plants, we successfully discovered several 
plants that contain compounds with remark-
able anticancer activity against three human 
tumor cell lines, colon HT-29, lung A549, and 
gastric MKN1. Among these plants, we chose 
the Melia tree for further studies on the basis 
of the strong anticancer activity of its com-
pounds in vitro and in vivo. 
Materials and methods
Preparation of MLE
The Melia leaves, obtained from Nago Muni- 
cipality (Okinawa, Japan), were washed and 
dried at 65°C overnight. The samples were 
powdered and suspended in nine volumes of 
distilled water. The suspension was incubated 
at 60°C for 3 h and centrifuged at 9400 × g for 
30 min. After centrifugation, the supernatant 
was dried by evaporation, and the dried mate-
rial was suspended in distilled water at a con-
centration of 10.5 mg/ml; this suspension 
(crude extract) was tested for toxicity as 
described in the following section. The suspen-
sion was filtered through a 10-kDa cutoff mem-
brane filter (Pellicon 2 Mini Filters; Millipore 
Corporation, Germany), and the filtrate was 
used as a 10.5 mg/ml sample of M. azedarach 
leaf extracts (MLE). 
Toxicity test of the crude extract
To determine the fraction with most toxicity, the 
crude extract was filtered through various mo- 
lecular weight cut-off membrane filters (Viva- 
spin 20: Sartorius); VS2091 (3,000 Da cut-off), 
VS2011 (5,000 Da cut-off), VS2001 (10,000 
Da cut-off), VS2041 (100,000 Da cut-off), and 
VS2051 (300,000 Da cut-off). The toxicity of 
the six filtrate samples was tested in mice; 
4-week-old female ddY (SPF) mice (n = 5; Japan 
SLC Co., Ltd.) were intraperitoneally adminis-
tered 0.5 ml of the samples per day, diluted to 
1.5 mg/ml. On day 170, the mice were eutha-
nized by administering an excess of pentobarbi-
tal via intraperitoneal injection. The livers, 
spleens, kidneys, hearts, and lungs were then 
excised and weighed. The organs were fixed in 
10% formalin (060-03845: Wako Pure Che- 
mical Industries Ltd.) and sliced into 4-μm-thick 
sections, followed by hematoxylin and eosin 
(H&E) staining. All animal experiments were 
carried out in specific pathogen-free (SPF) con-
ditions in accordance with the Fundamental 
Rules for Animal Experiments and the Gui- 
delines for Animal Experiments Performed at 
The Institute of Biological Resources, published 
by the Animal Welfare and Animal Care Com- 
mittee, including the Animal Ethics Committee 
of the Institute of Biological Resources 
(Okinawa, Japan).
Cell culture
The colon (HT-29), lung (A549), and gastric 
(MKN1) cancer cell lines (used for biological 
assays of MLE) were obtained from the Division 
of Molecular Pharmacology of Cancer Chemo- 
therapy Center of the Japanese Foundation for 
Cancer Research (Tokyo, Japan). The HT-29 
(JCRB 1383), A549 (JCRB 0076), and MKN1 
(JCRB 0252) cancer cell lines (used for molecu-
lar mechanism analysis of MLE) were purcha- 
sed from the Japanese Collection of Research 
Bioresources (JCRB) Cell Bank. The cells were 
cultured in Roswell Park Memorial Institute 
1640 (RPMI 1640) medium (Gibco; Life Tech- 
nologies) supplemented with 10% fetal bovine 
serum (FBS_F9423: Sigma-Aldrich). IMR90 
and J774A.1 cells were purchased from the 
American Type Culture Collection and cultured 
in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% FBS.
Measurements of cell growth inhibition
Cell growth inhibitory capacity of the plant 
extracts was measured as described previously 
[11-13]. Briefly, 10,000 cells were seeded into 
each well of 96-well plates in RPMI 1640 with 
5% fetal bovine serum and allowed to attach 
overnight. The extracts were prepared in a 
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series of dilutions (10-1-10-8) in RPMI 1640 
medium, and 100 µl of the extract was added 
to each well and incubated for 2 days. Subse- 
quently, cell growth was determined according 
to the sulforhodamine B assay [14] as follows: 
the cells were washed five times with 1% acetic 
acid and incubated with 50 µl of 0.4% sulforho-
damine B (in 1% acetic acid; Wako Pure Che- 
mical Industries Ltd., Osaka, Japan). Then, 150 
µl of 10 mM unbuffered Tris reagent (pH 10.5; 
Wako Pure Chemical Industries Ltd.) was added 
to each well, and the absorbance was mea-
sured at 525 nm using a standard plate reader. 
The concentration of test samples inhibiting 
50% of the cell growth (GI50) was determined 
using the results of the above experiment. 
Cell cycle analysis
MKN1 cells were cultured at an initial density of 
2 × 105 cells/well in the presence or absence of 
MLE (105, 10.5, and 1.05 µg/ml) or mitomycin 
C (1 mg/ml, 139-18711: Wako Pure Chemical 
Industries Ltd.). At 1 and 2 days after initial 
seeding, the cells were ethanol-fixed and 
washed with PBS and incubated with 0.5 mg/
ml RNase A (Sigma, R4875) for 30 min at 37°C. 
Cells were then stained with propidium iodide 
(Wako, 169-26281) and subjected to flow 
cytometry using a FACS Calibur (Japan BD 
Biosciences, Tokyo, Japan). FlowJo V10.4.2 (BD 
Biosciences) was used to analyze the results.
Immunoblot analysis
Cells were incubated with lysis buffer (50 mM 
Tris-HCl [pH 7.5], 150 mM sodium chloride, 1 
mM ethylenediaminetetraacetic acid, 1% NP- 
40, and protease inhibitor cocktail [cOmplete 
Mini, Roche]). Proteins in the cell lysate were 
separated using sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis and transferred 
to polyvinylidene difluoride membranes (Immo- 
bilon P, Merck Millipore). The membranes were 
then incubated with primary antibodies, and 
the immunoreactive proteins were visualized 
using anti-rabbit or anti-mouse IgG conjugated 
to horseradish peroxidase (RPN1231-2ML: GE 
Healthcare), followed by detection using an 
Enhanced Chemiluminescence (ECL) Detection 
System with film (GE Healthcare). The primary 
antibodies used were as follows: Anti-LC3 (light 
chain 3, PM036) was purchased from Medical 
& Biological Laboratories Co., Ltd. Anti-cleaved 
caspase 3 (Asp 175, clone 5alE, #9664S), anti-
cleaved poly-ADP ribose polymerase (PARP) 
(Asp 214, human-specific, #9541S), and anti-
glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH, rabbit mAb 14C10, #2118L) were pur-
chased from Cell Signaling Technology Japan, 
K.K. (Tokyo, Japan). 
Tumor formation assay
MKN1 cells (106 cells) were subcutaneously 
injected into BALB/c Slc-nu/nu (SPF) female 
mice (5 weeks old, Japan SLC, Inc.). When 
tumor sizes reached 50-150 mm3, the mice 
were orally administered 0.5 ml MLE (1.5 mg/
ml) every 4 days over a 3-week period. Tumor 
growth and body weight were monitored daily. 
Tumor volumes were determined using the 
standard formula: V = 4πab2/3 (V: tumor vol-
ume, 2*a: the major axis, 2*b: the minor axis).
Transmission electron microscopy (TEM)
Cells were washed, fixed in 2.5% glutaralde-
hyde for 30 min at 25°C, treated with 2% osmi-
um tetroxide, dehydrated in a graded series of 
ethanol baths, infiltrated, and embedded in 
resin. Then, 50-nm-thick sections were cut 
using a Leica EM UC6 Ultramicrotome (Leica 
Microsystems), followed by staining with 4% 
uranyl acetate and 2% lead citrate, and visual-
ization by TEM using a JEOL JEM-1230R elec-
tron microscope (JEOL, Ltd.) at an accelerating 
voltage of 100 kV.
Structure analysis of constituents in MLE
MLE (2 g/100 mL) was fractionated by C18 
reversed-phase chromatography with 0.1% for-
mic acid/acetonitrile (ACN) using a six-step gra-
dient (20, 30, 40, 50, 60, and 70% ACN (v/v)). 
Six fractions were obtained (AF28, AF37, AF46, 
AF55, AF64, and AF73). Each fraction was 
evaporated and dried to obtain 2044, 53.6, 56, 
9.1, and 3.3 mg of AF28, AF37, AF46, AF55, 
and AF64, respectively. No significant amount 
of material was recovered from the AF73 frac-
tion. The fractions with anti-proliferative activity 
were subjected to high-performance liquid 
chromatography (Cosmosil AR-II, 20 × 250 mm) 
using a 0.1% formic acid/methanol (MeOH) gra-
dient (MeOH concentration: 50% for 0-5 min, 
50-55% for 5-9 min, 55% for 9-15 min, 55-70% 
for 15-22 min, and 70% for 22-27 min) to yield 
compounds with possible biological activities. 
The structures of the isolated compounds were 
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analyzed using nuclear magnetic resonance 
(NMR) spectroscopy and mass spectrometry 
(MS).
Statistical analysis
Statistically significant differences between 
groups were determined using Student’s t-test, 
Wilcoxon test, or a SAS mixed procedure. P- 
values less than 0.05 were considered statisti-
cally significant. Values are expressed as the 
means of triplicate samples ± the standard 
error of the mean. 
Preclinical evaluation of MLE in canine can-
cers in veterinary hospitals
Dogs were orally administered, once or twice a 
day, with 0.5, 1.0, and 1.5 ml MLE for dogs with 
< 5, 15-20, and > 20 kg body weight, respec-
tively. Thirty-three dogs with various cancers 
from 15 veterinary hospitals in Niigata (2 Hos- 
pitals), Fukushima (1), Tokyo (2), Saitama (1), 
Shizuoka (2), Aichi (2), Gifu (1), Osaka (1), and 
Okinawa (3) prefectures were tested. Dogs 
were divided into test (n = 25) and placebo 
(only glycerin, n = 8) groups. Dogs previously 
treated with anticancer or immune compounds 
were excluded from this study. The following 
factors were evaluated: appetite, locomotor 
activity, body weight, tumor size, metastasis, 
and recurrence. The investigation was under-
taken over a 6.5-month period. The test and 
placebo groups were clinically treated in accor-
dance with the general guidelines and the 
Research Council guide for the care and use of 
animals of each hospital.
Results 
Initial screening of anticancer compounds 
from subtropical plants 
We searched for anticancer substances from 
more than 2,000 subtropical plants collected 
in Okinawa, and at least 10 plants were found 
to possess anticancer compounds. Particularly, 
crude extract from Melia tree leaves appeared 
to show high anticancer activity against colon 
(HT-29), lung (A549), and gastric (MKN1) can-
cer cells (Table 1). The concentrations of Melia 
leaf extract inhibiting 50% (GI50) of HT-29, 
A549, and MKN1 cell growth were 0.31, 1.50, 
and 1.30 µg/0.1 ml, respectively. These GI50 
values were, except for that of A549 cells, prin-
cipally similar to those of mitomycin C, which 
was used as the control anticancer drug. The 
crude extract of Melia tree leaves, however, 
unexpectedly appeared to contain toxic sub-
stances against mice. Therefore, the identifica-
tion of toxic fractions was essential for the 
extract to be used for cancer treatment.
Identification of highly toxic components from 
the crude extract
When the crude extract of Melia tree leaf was 
intraperitoneally administered to mice, with 
varying doses, all 10 mice died within 2 h; path-
ological analysis revealed that their livers were 
largely swollen, and centrilobular necrosis and 
congestion was observed (Table 2). Splenic 
and myocardial necrosis were also observed. 
Although the livers did not show hemorrhage, 
hemorrhagic spots were observed in the heart 
(data not shown). However, mice that were oral-
ly administered the crude extract survived 
(Table 3). These results suggested that the 
crude extract contains substances that are 
toxic for mice when administered peritoneally.
To find the toxic fraction in the extract, the 
extract was filtered through various molecular 
weight cut off membrane filters, and the fil-
trates were tested for their toxicity against 
mice. Intraperitoneal administration of the 
300-kDa cut-off filtrate, which contained only 
components of the crude extract under 300 
kDa, resulted in 80% death of the treated mice 
(Table 3). The histopathological features in 
mice killed by the 300-kDa-cut-off filtrate were 
similar to those in mice killed by the crude 
extract, although splenic necrosis was observed 
only in mice administered the unfiltered crude 
Table 1. Comparison of anticancer activity between MLE and Mitomycin C
Initial screening of anticancer compounds using three tumor cell lines
Tumors Cell lines GI50* of crude extract from Melia tree leaf (μg/0.1 ml) GI50* of Mitomycin C (μg/0.1 ml)
Lung cancer A549 1.50 0.29
Colon cancer HT-29 0.31 0.31
Gastric cancer MKN1 1.30 1.42
*GI50: concentration inhibiting 50% of cell growth.
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extract (Table 2). The toxicity was thus elimi-
nated from unfiltered crude extract if the com-
ponents over 100 kDa were removed. Death 
and histological abnormalities were not obser- 
ved in mice intraperitoneally administered fil-
trates filtered through 100-, 10-, 5-, and 3-kDa 
cut-off membrane filters. Therefore, in all fur-
ther experiments, only the 100-kDa cut-off fil-
trate was used as the MLE solution.
Growth inhibition activity of MLE against vari-
ous cancer cell lines
To characterize the anticancer activity of MLE, 
the growth inhibitory effect of MLE against 39 
cancer cell lines was examined (Table 4). MLE 
showed anticancer activity against a panel of 
39 cancer cells with GI50 ranging from 0.11 
µg/0.1 ml against the BSY-1 breast cancer cell 
Table 2. Pathological changes in extract-treated mice 
Administered extract
Cut-off molecular weights of the membrane filters
Unfiltered 300 kDa 100 kDa 10 kDa 5 kDa 3 kDa Control (PBS)
Massive necrosis in the liver - - - - - - -
Centrilobular necrosis in the liver ++ ++ - - - - -
Congestion in the liver +++ +++ - - - - -
Hemorrhage in the liver - - - - - - -
Splenic necrosis ++ - - - - - -
Myocardial necrosis ++ + - - - - -
+++: Severe, ++:  Moderate, +: Mild, -: No particular; PBS: Phosphate buffered saline.
Table 3. The mortality rate in mice administered various extracts of Melia tree leaf
Route of administration Unfiltered
Cut-off molecular weights of the membrane filters
Control (PBS)
300 kDa 100 kDa 10 kDa 5 kDa 3 kDa
Intraperitoneal administration *5/5 4/5 0/5 0/5 0/5 0/5 0/5
Oral administration 0/5 0/5 0/5 0/5 0/5 0/5 0/5
*Number of dead mice/number of mice in group; PBS: Phosphate buffered saline.
Table 4. Evaluation of anticancer activity against nine tumors consisting of 39 tumor cell lines
Tumors Cell lines GI50* 
(μg/0.1 ml)
Tumors Cell lines GI50* 
(μg/0.1 ml)
Tumors Cell lines GI50* 
(μg/0.1 ml)
Breast Cancer HBC-4 1.50 Lung Cancer NCI-H23 1.50 Kidney Cancer RXF-631L 0.64
BSY-1 0.11 NCI-H226 0.90 ACHN 1.50
HBC-5 1.50 NCI-H522 0.97
MCF-7 1.50 NCI-H460 1.50
MDA-MB-231 0.90 A549 1.50
DMS273 0.24
DMS114 1.28
Brain Cancer U251 1.50 Skin Cancer LOX-IMVI 0.88 Gastric Cancer St.4 0.49
SF-268 1.50 MKN1 1.50
SF-295 0.44 MKN7 1.50
SF-539 1.50 MKN28 1.50
SNB-75 1.50 MKN45 0.52
SNB-78 1.50 MKN74 0.77
Colon Cancer HCC2998 0.82 Ovarian Cancer OVCAR-3 0.88 Prostate Cancer DU-145 1.50
KM-12 1.34 OVCAR-4 1.28 PC-3 1.50
HT-29 0.14 OVCAR-5 1.50
HCT-15 1.50 OVCAR-8 1.16
HCT-116 0.41 SK-OV-3 1.50
*GI50: concentration inhibiting 50% of cell growth.
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line to 1.5 µg/0.1 ml in many other cancer cell 
lines. The anticancer activities of MLE against 
the 39 cancer cell lines showed significant dif-
ferences, even among cell lines from the same 
cancers. As previously reported [13, 15], we 
also established a panel of these 39 cancer 
cell lines and developed a database of their 
chemosensitivities, in which various drugs were 
profiled for their “fingerprints” patterns of dif-
ferential activity against these cell lines [15]. A 
significant correlation between a drug’s finger-
print and its mode of action was observed. 
Based on the fingerprint database, the mecha-
nism of anticancer activity of MLE was found to 
involve vacuolar-type H+ ATPase inhibition 
because the fingerprint pattern of MLE was 
highly similar to that of bafilomycin, which is a 
well-known vacuolar-type H+ ATPase inhibitor.
MLE efficiently prevented tumor growth in vivo
To determine whether the strong anticancer 
activities observed against various cancer cell 
lines can influence the tumor growth in an in 
vivo mouse model, we transplanted MKN1 gas-
tric cancer cells into nude mice (Figure 1). After 
the size of the tumors reached 50-150 mm3, 
the oral administration of MLE was started. The 
administration significantly reduced the growth 
of the tumor. In PBS-treated mice, the tumor 
size increased from 100% on the first day of the 
administration to 200% and 300% on days 7 
Figure 1. MLE suppresses tumor growth in the mouse xenograft model. Three mice (BALB/c Slc-nu/nu) were in-
jected with 106 MKN1 cells (A-C) or HT-29 cells (D) subcutaneously and were orally administered with 0.5 ml of MLE 
solution (1.5 µg/ml) or PBS every 2 days. The administration started when tumors reached a volume of 50-150 
mm3. Average tumor volume was plotted with standard error (SE) against days after the administration. The tumor 
growth period between PBS- and MLE-administered mice were analyzed using SAS mixed procedure, and P value 
was determined (A). Mice were euthanized at 21 days after the administration, and the photographs of euthanized 
mice are shown; red arrows indicated tumors (B). Tumors of MLE-administered mice were histopathologically ex-
amined after H&E staining (C). The infiltrated mononuclear-like cells (indicated by arrow) were also examined with 
electron microscopy (inset in C). The thin sections of tumors were also Giemsa stained, and the M phase cells were 
analyzed (D). 
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and 12, respectively. In contrast, tumors in 
MLE-administered mice were approximately 
two-fold smaller than those in PBS-treated 
mice at 12 days after the start of the adminis-
tration. The result indicated that MLE treatment 
efficiently suppressed tumor growth (Figure 
1A). We observed the effect of MLE administra-
tion until day 21. The difference in the appear-
ance of tumors between MLE-administered 
mice and PBS-administered mice was signifi-
cant (Figure 1B). Similar results were obtained 
in the mice transplanted with HT-29 colon can-
cer cells (data not shown).
Histopathological analysis of tumors from 
MLE-administered mice
Histopathological analysis of MKN1 cell-trans-
planted mice demonstrated the difference 
between the tumors from MLE-administered 
and PBS-administered mice. In H&E-stained 
sections of the tumors from MLE-administered 
mice, infiltrates of mononuclear-like cells were 
observed at the peripheral tumor sites. The 
dead gastric cancer MKN1 cells were enclosed 
with infiltrated cells, which showed structures 
characteristic of NK cells (Figure 1C). 
HT-29 colon cancer cells were also analyzed. 
The observation of Giemsa-stained tumor slic-
es revealed differences between images of M 
phase cells in MLE-treated and PBS-treated 
tumors. Cell-division images were more often 
observed in MLE-treated tumors than in con-
trol-treated tumors (Figure 1D). For quantita-
tive analysis, we examined the frequency of 
metaphasic cells in the proliferating cell popu-
lation. Proliferating cells were defined as Ki67-
positive cells. The number of proliferating cells 
and metaphasic cells in five fields were counted 
under a microscope at 200x magnification. The 
percentage of metaphasic cells among the pro-
liferating cells was about 2 times higher in 
tumors from PBS-treated mice than that in 
tumors from MLE-treated mice: 10.5% in PBS-
treated mice and 4.7% in MLE-treated mice.
To examine the possibility of apoptosis induc-
tion by MLE treatment, TUNEL (terminal deoxy-
nucleotidyl transferase dUTP nick-end labeling) 
staining of thin tumor sections was attempted. 
In MLE-treated gastric cancer tissue, much 
higher TUNEL-positive cells were observed than 
in PBS-treated ones (data not shown).
Activation of macrophages by MLE
The presence of infiltrated cells in tumors from 
MLE-administered mice suggested that MLE 
might activate immunological cells. To examine 
the possibility, J774A.1 mouse macrophage 
cells were treated with MLE, and the released 
tumor necrosis factor (TNF)-α was measured 
by ELISA. As expected, MLE markedly induced 
the release of TNF-α, an important antitumor 
cytokine, from the macrophages (Figure 2). 
Suppression of MKN1 cell proliferation by MLE
To elucidate the tumor suppression activity of 
MLE, we investigated the effect of MLE on 
MKN1 cells in vitro. The number of MKN1 cells, 
treated with either 105 or 10.5 µg/ml of MLE, 
significantly decreased as compared to those 
treated with PBS (Figure 3A), which was consis-
tent with the observed antitumor activity. In 
contrast, MLE hardly affected the proliferation 
of human normal fibroblast cells (IMR90; Figure 
3B). Unexpectedly, we observed that the num-
ber of trypan blue positive MKN1 cells was 
unaltered for 2 days in the presence or absence 
of MLE (Figure 3C), suggesting that MLE did not 
affect the viability of MKN1 cells during the 
experimental period. Thus, MLE efficiently pre-
vented tumor growth in vivo and in vitro while it 
did not directly cause cell death but suppressed 
cell proliferation.
Figure 2. Activation of macrophages by MLE. J774A.1 
mouse macrophage cells were treated with MLE, 
PBS, or LPS (Lipopolysaccharide from E. coli O55 
served as a positive control) for 24 h. Cell culture 
supernatants were collected, and TNF-α levels were 
measured using ELISA (R&D Systems). Two different 
lots of MLE (LOT 28 and LOT 28) were compared. Sta-
tistically significant differences between group mean 
values were determined using the Wilcoxon test.
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Figure 3. Effect of MLE on cellular proliferation in vitro. MKN1 cells (A) and IMR90 cells (B) were cultured in the 
presence or absence of MLE or mitomycin C at an initial density of 2 × 105 or 105 cells/well, respectively. Viable 
cells were counted 1 and 2 days after seeding. The MLE- or PBS-treated cells were further cultured for 2 days, 
and live and dead cells were counted using trypan blue staining (C). (D) Cell cycle analysis of MKN1 cells. Cell 
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To elucidate the mechanisms of the MLE-
induced suppression, we first performed cell 
cycle analyses. Cell cycle progression was 
retarded, and the percentage of sub G1 frac-
tion appeared to be increased by MLE treat-
ment (Figure 3D). We examined the involve-
ment of apoptosis in the retardation of the cell 
cycle. However, western blot analysis revealed 
no increase in cleaved caspase 3 and cleaved 
PARP1 expression in MLE-treated cells (Figure 
3E) in contrast to the cells treated with mitomy-
cin C, which is well-known to induce apoptosis. 
The result suggested that MLE affected cell 
proliferation by mechanisms other than apop- 
tosis.
MLE induces autophagy
We then examined the intracellular structure of 
MLE-treated MKN1 cells using TEM. We obser- 
ved autophagosome-like structures (Figure 
4A). In addition, autophagy markers, LC3 I and 
LC3 II, were significantly expressed in MLE-
treated MKN1 cells (Figure 4B and 4C). These 
data suggest that cell growth suppression by 
MLE was due to autophagy of one of the 
mechanisms.
Preclinical evaluation of MLE treatment effi-
cacy for canine cancer
To evaluate the efficacy of MLE treatment in 
higher vertebrates, we performed preclinical 
evaluations in 33 dogs with various cancers, 
including breast, liver, osteosarcoma, bladder, 
melanoma, mastocytoma, chromaffinoma, and 
thyroid carcinoma in 15 veterinary hospitals 
(Figure 5B). Dogs were divided into two groups 
(MLE: n = 25 and placebo: n = 8). We found that 
cancer progression was significantly ameliorat-
ed by MLE treatment in 76% of the dogs, com-
pared to that in the placebo group (Figure 5A). 
Importantly, no abnormal and adverse reac-
tions were observed in dogs. Thus, it could be 
concluded that MLE efficiently prevents cancer 
progression in dogs. These results suggested 
that MLE administration may be useful to treat 
cancer in humans and dogs. Furthermore, 14 
major canine cancers, including hepatocellular 
carcinoma, osteosarcoma, and multiple my- 
eloma, appeared to be markedly ameliorated 
(Figure 5B).
Identification of chemical compounds with 
anti-proliferative activity
To identify the constituents in MLE, a six-step 
gradient (20%, 30%, 40%, 50%, 60%, and 70% 
ACN v/v as eluate) separation process using C18 
reverse-phase chromatography was carried 
out. We isolated five fractions (AF28, AF37, 
AF46, AF55, and AF64) and evaluated their 
antiproliferative effects. We found that the 
components of AF46, AF55, and AF64 had anti-
proliferative effects, whereas the components 
of AF28 and AF37 barely showed any effects 
(Figure 6A).
We next determined the structures of the com-
pounds in MLE using NMR and MS. AF46, AF55, 
and AF64 all contained azedarachin B-related 
moieties (Figure 6B). AF46 contained 12-hydro- 
xyamoorastatone and 12-hydoroxyamoorasta- 
tin; AF55 contained 12-O-acetylazedarachin B, 
meliatoxin B2, and toosendanin; and AF64 con-
tained azedarachin B, 12-diacetyltrichilin, 3- 
diacetyltrichilin H, neoazedarachin B, and 7, 14 
epoxyazedarachin B.
Discussion
In this study, we demonstrated the definite anti-
cancer activity in vitro and in vivo of an extract 
from M. azedarach L. (Melia tree), found in the 
subtropical Okinawa. Plant extracts have been 
adopted for the treatment of various diseases 
[16, 17]. Particularly, limonoids have been 
investigated for possible use as medicinal rem-
edies in humans and animals [5]. In this study, 
we showed that extracts of M. azedarach L. 
leaves contain compounds that are cytotoxic to 
cancer cells but not to normal cells (Tables 1, 
4; Figure 3A, 3B). Similar cytotoxic activity was 
previously reported for the extracts from the 
cycle progression was analyzed using flow cytometry after treatment with MLE for 3 days. Data is representative 
of three independent experiments. The percentage of SubG1 phase cells from the replicates is also represented. 
(E) Immunoblot analysis of cleaved caspase 3 and cleaved PARP1. GAPDH serves as a loading control. Data are 
representative of two independent experiments. Bands were quantified by densitometry (right end). Statistically 
significant differences between group mean values were determined using the Student’s t-test (***P < 0.001, **P 
< 0.01, and *P < 0.05).
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Figure 4. MLE induces autophagy in MKN1 cells. A. Representative images of MLE-treated MKN1 cells acquired by 
transmission electron microscopy. Autophagosomes highlighted in the square region are indicated via a zoomed-in 
image. Scale bars: 2 μm and 0.5 μm (zoomed). B. Immunoblot analysis of LC3. GAPDH serves as a loading con-
trol. Data is representative of three independent experiments. Bands were quantified by densitometry (right end). 
C. FACS analysis of LC3-expressing cells and fold change of Median fluorescence intensity (MFI). Cells that were 
serum-starved for 4 h were used as positive controls. Data from two independent experiments are represented. 
Statistically significant differences between group mean values were determined using the Student’s t-test (***P 
< 0.001, **P < 0.01, and *P < 0.05).
bark, roots, and seeds of M. azedarach L. [18-
22]. However, their underlying mechanism of 
activity remains elusive. We prepared the 
extract from leaves instead of bark, roots, or 
seeds of M. azedarach L. and showed that the 
extract induced autophagy in MKN1 gastric 
cancer cells (Figure 4). In contrast, toosend-
anin, which was identified in fraction AF55 in 
our study, was reported to induce apoptosis in 
U937 cancer cells [23]. In contrast, apoptosis 
induction was not detected in MLE-treated 
MKN1 cells (Figure 3E), but an increase in the 
number of TUNEL-positive cells was observed 
in tumors from MLE-treated mice (data not 
shown). These results suggest that MLE might 
inhibit cell growth depending on the type of 
cancer cells. Therefore, it was necessary to 
examine the effect of MLE on other cancer cell 
Anticancer activities of Melia azedarach L. leaf extracts
591 Am J Cancer Res 2020;10(2):581-594
types, which might reveal different mecha-
nisms of cell death, such as apoptosis, necrop-
tosis, or autophagy. Since various canine can-
cers were ameliorated by MLE treatment, dif-
ferent cytotoxic activities might have affected 
different cancers. Since we did not observe 
severe adverse effects in MLE-treated dogs, 
MLE might be useful as oral cancer therapeu-
tics without remarkable side effects. 
A few studies have suggested that autophagy 
induction is an effective strategy for cancer 
treatment [24]. However, various recently pub-
lished studies indicate that autophagy induc-
tion helps the survival of adjacent cancer cells 
following chemotherapy [25, 26], and autopha-
gy inhibitors have been used in combination 
rification of the intracellular mechanism by 
which MLE induces autophagy would help guide 
its therapeutic use.
Data showing that autophagy is regulated by 
cytokines in various biological contexts have 
been accumulating [39, 40]. For instance, 
TNF-α could play a role in stimulating autopha-
gy, although the underlying mechanism has not 
been well established. The mechanisms might 
differ among cell types [41-44]. Conversely, 
autophagy affects the transcription of cytokine 
genes and secretion of cytokines [45, 46]. The 
autophagy inhibitor 3-methyladenine suppress-
es TNF-α transcription and secretion [47, 48]. 
Although we observed increased levels of TNF- 
α in MLE-treated macrophages in vitro, it is 
Figure 5. Effects of MLE on various cancers in dogs. A. Comparative ef-
ficacy of MLE against canine cancers; yellow, amelioration; red, complete 
response; light blue, aggravation; dark blue, severe aggravation. B. Clas-
sification of therapeutic efficacy of MLE on different canine cancers. The 
degree of MLE efficacy is shown on the left. Cases of treatment efficacy 
and MLE therapeutic efficacy on a large number of canine cancers are 
also described in the center and the right of the table.
with anticancer drugs [27-30]. 
Accordingly, the development of 
potential anticancer drugs with 
autophagy-inducing activity may 
be an effective strategy in can-
cer therapy [31]. 
An important observation--ma- 
de in a study that addressed 
the mechanism of tamoxifen 
resistance--was that although 
tamoxifen induced autophagy 
[32], whether the autophagy 
was cytotoxic or rendered sur-
viving cells tamoxifen-resistant 
was unclear [33, 34]. Eventually, 
tamoxifen-induced autophagy 
was shown to be cytotoxic to 
cancer cells due to autophagic 
degradation of cellular k-Ras 
protein [35]. Cells that lack 
k-Ras lose viability. In addition, 
in response to stress, c-Jun 
N-terminal kinase (JNK) was 
activated, phosphorylating B- 
cell lymphoma-2 (Bcl2) or BIM to 
dissociate Beclin from Bcl2, 
which led to the formation of an 
active Beclin1-VPS34 complex 
responsible for autophagy in- 
duction [36]. In summary, cellu-
lar stress can induce cell growth 
arrest or death. Some antitumor 
drugs that inhibit the mammali-
an target of rapamycin complex 
1 (mTORC1), a negative regula-
tor of the autophagic pathway, 
induce autophagy [37, 38]. Cla- 
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unclear whether TNF-α induction by MLE is 
associated with a reduction of tumor growth in 
vivo. Further investigation of crosstalk between 
immunological cells and cancer cells would elu-
cidate the mechanism of MLE-induced retarda-
tion of cancer development.
In this study, we not only identified MLE as an 
autophagy-inducing agent but also found that 
MLE treatment reduced the growth of multiple 
cancers in clinical tests with dogs and cats. 
Further studies should be conducted to exam-
ine whether cells that underwent autophagy fol-
lowing MLE treatment were killed. In addition, 
the development of therapeutic reagents 
against human cancers derived from MLE 
should be explored.
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